期刊文献+

碱性蒙脱石抗酸剂性能测定及评价 被引量:6

Determination and Evaluation of Antacid Property of Alkaline Montmorillonite
原文传递
导出
摘要 目的对碱性蒙脱石抗酸剂进行性能测定及评价。方法测定抗酸剂的活性成分含量、溶解度及粒度等参数,并进行BET、X-射线衍射法(XRD)和扫描电镜(SEM)表征分析,通过急性毒性实验、体外抗酸实验以及胃黏膜保护实验对抗酸剂进行评价。结果活性成分Ca(OH)2的含量和溶解度分别为37%和84 mg·L-1,活性成分Ca(OH)2负载比较牢固,碱强度大大下降。粒度和比表面积分别为8.3μm和37.5 m2·g-1,有利于吸附胃酸和形成胃黏膜保护。X-射线衍射法表征结果显示,抗酸剂保留了蒙脱石的结构,扫描电镜图谱显示,抗酸剂的表面比较光滑,利于黏膜保护。急性毒性实验、体外抗酸实验和胃黏膜保护实验结果表明,抗酸剂安全无毒,并表现出优良的抗酸和胃黏膜保护性能。结论碱性蒙脱石抗酸剂是一种优良的抗酸剂及胃黏膜保护剂。 OBJECTIVE To investigate and evaluate the antacid property of alkaline montmorillonite. METHODS Parameters of the antacid,such as active component content,solubility,and granularity,were determined. The antacid was characterized by BET,XRD,and SEM,and evaluated by acute toxicity test,acid resistance in vitro experiment,and gastric mucosa protection experiment.RESULTS The content and solubility of the active component Ca( OH)2were 37% and 84 mg·L- 1,respectively,which showed that Ca( OH)2was relatively firmly loaded and the alkalinity was largely decreased. The granularity and specific area were 8. 3 μm and37. 5 m2·g- 1,respectively,which were beneficial to gastric acid adsorption and gastric mucosa protection. Besides,XRD characterization results revealed the antacid retained a structure of montmorillonite. And SEM patterns indicated the surface of the antacid was relatively smooth,which was conducive to gastric mucosa protection. In addition,the results of acute toxicity test,acid resistance in vitro experiment,and gastric mucosa protection experiment demonstrated that the antacid was safe and non-toxic. Meanwhile,it pocessed excellent properties of acid resistance and gastric mucosa protection. CONCLUSION Alkaline montmorillonite antacid is an excellent antacid and gastric mucosa protectant.
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第2期157-162,共6页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(21166004)
关键词 碱性蒙脱石 抗酸剂 胃黏膜保护剂 alkaline montmorillonite antacid gastric mucosa protectant
  • 相关文献

参考文献1

二级参考文献34

  • 1[1]Huber R, Kohl B, Sachs G, et al. The continuing development of proton pump inhibitors with particular reference to pantorazole [J]. Aliment Pharmacol Ther , 1995,9:363. 被引量:1
  • 2[2]Blum RA.Lansoprazol and omeprazol in the treatment of acid peptic disorders[J]. Am J Health-Syst Pharm , 1996,53:1401. 被引量:1
  • 3[3]Chiverton SG, Howden CW, Burget DW, et al. Omeprazole (20 mg)daily given in the morning or evening: a comparison of effects on gastric acidity,and plasma gastrin and omeprazole concentration[J] .Aliment Pharmacol Ther,1992,6:103. 被引量:1
  • 4[4]Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole: implication for anti-unlcertherapy[J]. Dig Dis Sci, 1994,39(1):161. 被引量:1
  • 5[5]Bergatrand R.Decreased oral bioavialability of lansoprazole in healthy clunteeres when given with a standardized breakfast[J]. Clin Drug Invest, 1995,9:67. 被引量:1
  • 6[6]Katz PO, Anderson C, Khoury R, et al, Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors[J]. Aliment Pharmacol Ther , 1998,12:1231. 被引量:1
  • 7[7]Ishizaki T, Horai Y.Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole [J] . Aliment PharmacolTher, 1999,13 (Suppl 3) :27. 被引量:1
  • 8[8]Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion[J]. Eur J GastroenterolHepatol, 1999,11:1277. 被引量:1
  • 9[9]Geus WP, Mulder JJ, van den Boo Mgaad DM, et al. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects[J]. Aliment Pharmacol Ther, 1998,12: 329. 被引量:1
  • 10[10]Horn J.The proton-pump inhibitors:similarities and differences[J].Clin Ther ,2000,22:266. 被引量:1

共引文献21

同被引文献52

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部